| Results of Scheme Meetings and Extraordinary General Meeting |
| 11 January 2010 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
In accordance with ASX Listing Rule 3.13.2, Unilife Medical Solutions Limited (Unilife or the Company) (ASX: UNI / OTCPK: UNIFF) is pleased to confirm that each of the resolutions put to shareholders and optionholders at the Court Ordered Scheme Meeting of Shareholders and Optionholders (as applicable) and the Extraordinary General Meeting held on 8 January 2010 were passed. The resolutions related to the following matters: SHARE SCHEME MEETING
OPTION SCHEME MEETING
EXTRAORDINARY GENERAL MEETING
Further details of the results of the resolutions are set out in the attachment. Comment from Unilife Chief Executive Officer Alan Shortall "Shareholders have voted overwhelmingly in favour of our redomiciliation to the US. We consider this to be a resounding vote of shareholder confidence in our plans to consolidate our position as a US-based global leader in the design, development and supply of innovative safety medical devices. "We are now in a position to finalise preparations to list on the NASDAQ stock exchange. Subject to the SEC declaring our registration statement effective and NASDAQ approving our listing application, trading on the NASDAQ exchange is expected to commence in mid-February. "I believe these steps will help consolidate our position as a sustainable global business with the necessary expertise and operational capabilities to service the needs of an expanding network of pharmaceutical and healthcare customers. It will also help us build relationships with US-based investors that have a firm understanding of global pharmaceutical and healthcare markets. "The Board and I are confident that Unilife will continue to deliver upon key commercial and operational milestones for 2010. Over the coming 12 months we intend to complete our listing on NASDAQ, expand our base of US investors, complete the industrialisation program for the UnifilTM 1mL syringes, strengthen our relationships with pharmaceutical and healthcare industry leaders, complete our new global headquarters in Pennsylvania and continue to build a world-class team. We look forward to building further value in the Company on behalf of all our shareholders." Unilife would also like to take this opportunity to inform shareholders and optionholders that Federal Court approval of the Schemes will be sought at 2.15pm on Thursday 14 January 2010 at Law Courts Building, Queens Square, Sydney, New South Wales.
1 The Chairman indicated that he would vote all his open usable votes in favour of each resolution and these have therefore been added to the proxies which were directed “for” the resolutions.
UNILIFE MEDICAL SOLUTIONS LIMITED SHARE SCHEME MEETING The number of votes cast on poll (including the proxy votes) was as follows:
The number of votes cast on poll (including the proxy votes) was as follows:
In accordance with section 251AA of the Corporations Act 2001, the following information is provided to Australian Stock Exchange Limited in relation to resolutions passed by members of Unilife Medical Solutions Limited at its extraordinary general meeting held on 8 January 2010.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||